Skip to content
aniracetam
EntityQ417630· pop 15· linked from 364 articles

aniracetam

Sign in to save

Also known as 1-p-anisoylpyrrolidin-2-one, 1-P-ANISOYL-2-PYRROLIDINONE, Referan

Aniracetam (brand names Draganon, Sarpul, Ampamet, Memodrin, Referan), also known as '''N-anisoyl-2-pyrrolidinone''', is a racetam which is sold in Europe as a prescription drug. It is not approved by the Food and Drug Administration for use in the United States as a prescription medication or dietary supplement. Despite the FDA's lack of approval, the drug is readily available over-the-counter in misbranded dietary supplements.

Key facts

Drug.Verifiedfields
changed
Drug.Watchedfields
changed
Drug.verifiedrevid
477164594
Drug.IUPAC_name
1-[(4-Methoxybenzoyl)]-2-pyrrolidinone
Drug.image
Aniracetam.svg
Drug.image_class
skin-invert-image
Drug.width
200
Drug.image2
Aniracetam3d.png
Drug.image_class2
bg-transparent
Drug.width2
175
Drug.tradename
Ampamet, Memodrin, Pergamid
Drug.legal_US_comment
Unapproved "New Drug" (as defined by 21 U.S. Code § 321(p)(1)). Use in dietary supplements, food, or medicine is unlawful; otherwise uncontrolled.
Drug.legal_AU
S4
Drug.routes_of_administration
By mouth
Drug.elimination_half life
0.5 hours
Drug.IUPHAR_ligand
4133
Drug.CAS_number
72432-10-1
Drug.ATC_prefix
N06

via Wikipedia infobox

~4 min read

Encyclopedic overview

8 sections
Contents
  • Medical uses
  • Pharmacology
  • Synthesis
  • Legality
  • Europe
  • Australia
  • See also
  • References

Aniracetam (brand names Draganon, Sarpul, Ampamet, Memodrin, Referan), also known as '''N-anisoyl-2-pyrrolidinone''', is a racetam which is sold in Europe as a prescription drug. It is not approved by the Food and Drug Administration for use in the United States as a prescription medication or dietary supplement. Despite the FDA's lack of approval, the drug is readily available over-the-counter in misbranded dietary supplements.

== Medical uses == Aniracetam has been used to treat dementia following stroke and in Alzheimer's disease. Results from human clinical trials were published in 1991 (one multi-center placebo-controlled study and a follow-up) and in 2011 (one open-label study).

Excerpted from Wikipedia’s “aniracetam” article, available under the CC BY-SA 4.0 licence.

Gallery (4)